A novel tumor-inhibiting protein.

Over a 14 week period, the leukemia cells engrafted to the bone marrow of the mice. The mice were then given doses of Ara-C, Angiocidin or a combination of both. The chemotherapy agent Ara-C, or cytosine arabinoside, is standard-of-treatment for AML and kills cancer cells by inhibiting DNA synthesis. Mice treated only with Angiocidin noticed a 63 % reduction in AML cells, while those treated with both experienced a 79 % decrease in AML cells. Mice treated with Ara-C by itself saw a reduced amount of only around 40 %. ‘One question we’d is whether Angiocidin would be able to get into the bone marrow,’ said Tuszynski.A fresh white paper from The Beryl Institute, ‘Occasions of Truth: Medical center Switchboards a Bottom-Line Concern,’ investigates what goes on during phone calls to the switchboards of 341 hospitals and medical centers in the united states and provides guidelines for enhancing switchboard customer support. Related StoriesLoyola Medication, Palos Community Medical center jointly release innovative telemedicine programGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanningHealthcare technology sociable event of the entire year opens entriesAs customer support increasingly turns into a differentiating element between hospitals, customers expect a far more customer-centric knowledge or likely will need their business elsewhere.